Innovative Technology for Personalized Drug Testing

Indian-origin researcher leads a team at Texas A&M to create a tool for tailored pharmaceutical testing.

Dr. Abhishek Jain, an Indian-origin researcher at Texas A&M University, and his team are developing vessel-chip technology to improve personalized pharmaceutical drug testing ().

Jain’s lab, which also has Dr Tanmay Mathur on the team, received a grant from Texas A&M Innovation to continue developing an advanced vessel-chip deployment platform for large-scale pharmaceutical testing.

India: The Preferred Destination for Clinical Trials
Latest report from PwC India and USAIC highlights the emergence of India as a favored destination for conducting clinical trials.

‘Did You Know?
Only about 12% of drugs that enter clinical trials ever make it to market approval. #vesselchip #personalizedtechnology #drugtesting’

Revolutionizing Drug Testing

According to him, this system can be used from discovery to the translational pipeline, where you can immediately initiate informed clinical trials of venous, vascular, and hematological diseases and know what the outcome on an actual human might be.

“You can fine-tune your clinical trials or reduce the length of the clinical trials and make them much more efficient,” he said in a university statement.

Jain and his lab have focused on creating blood and lymphatic vessel chips. These tissue-engineered microfluidic devices mimic human circulatory systems and provide a platform for preclinical drug discovery.

US FDA Likely to Approve Clinical Trials for Pig-to-human Organ Transplants
US Food and Drug Administration (FDA) is likely to okay to allow clinical trials for pig-to-human organ transplants.

His work has culminated in founding a startup company with his current and past trainees.

According to researchers, the Texas A&M Innovation Translational Investment Fund (TIF) grant will help build customer confidence by ensuring the vessel chips are reliable, reproducible, and automated for ease of use.

FDA Takes Steps to Improve Diversity in Clinical Trials
Diversity Summit focuses on research site needs related to knowledge and best practices to recruit, engage and retain diverse patient populations.

Jain said the momentum offered by the TIF also allowed him to hire Dr. Tanmay Mathur, a previous graduate student of Jain’s, to help make the startup successful.

Reference:

AngioMT: A MATLAB based 2D image-to-physics tool to predict oxygen transport in vascularized microphysiological systems - (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0299160)

Source-IANS

Physician's Lack Agreement – Patients Prefer Branded or Generic Drugs?
Generics are not widely used, despite cost advantage, due to a lack of information to patients and reluctance from physicians to prescribe generics - A Need to educate masses